Compare VIR & TGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | TGLS |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2019 | 2011 |
| Metric | VIR | TGLS |
|---|---|---|
| Price | $10.59 | $38.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $21.00 | ★ $55.75 |
| AVG Volume (30 Days) | ★ 1.8M | 323.1K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | $68,556,000.00 | ★ $370,984,000.00 |
| Revenue This Year | $257.66 | $12.44 |
| Revenue Next Year | N/A | $11.39 |
| P/E Ratio | ★ N/A | $30.57 |
| Revenue Growth | N/A | ★ 17.98 |
| 52 Week Low | $4.82 | $34.05 |
| 52 Week High | $12.00 | $61.34 |
| Indicator | VIR | TGLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 54.19 |
| Support Level | $10.00 | $37.43 |
| Resistance Level | $11.83 | $47.87 |
| Average True Range (ATR) | 0.62 | 1.34 |
| MACD | -0.08 | 0.29 |
| Stochastic Oscillator | 30.62 | 78.70 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.